Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101749 | 0.90 | RAF1 (0.64) | RAF1RIPK2MAPK13MAPK14MAPK12 | |
| SCHEMBL16990706 | 0.87 | RAF1 (0.62) | RAF1RIPK2MAPK13MAPK14MAPK12 | |
| SCHEMBL2944830 | 0.86 | RAF1 (0.66) | RAF1RIPK2MAPK13MAPK14MAPK12 | |
| SCHEMBL15574401 | 0.85 | RAF1 (0.77) | RAF1RIPK2MAPK13MAPK14MAPK12 | |
| SCHEMBL15574733 | 0.85 | HDAC1 (0.63) | RAF1RIPK2MAPK14 | |
| SCHEMBL13239632 | 0.84 | RAF1 (0.69) | RAF1RIPK2MAPK13MAPK14MAPK12 | |
| SCHEMBL668459 | 0.84 | RAF1 (1.00) | RAF1RIPK2MAPK13MAPK14MAPK12 | |
| SCHEMBL3175321 | 0.82 | RAF1 (0.73) | RAF1RIPK2MAPK13MAPK14FLT3 | |
| SCHEMBL4444438 | 0.78 | RAF1 (0.72) | RAF1RIPK2MAPK13MAPK14MAPK12 | |
| SCHEMBL668623 | 0.78 | RAF1 (0.80) | RAF1RIPK2MAPK13MAPK14MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| EP-1970375-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-20060199844-A1 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2006-09-07 | — | — | US | disclosed |
| EP-1562905-A2 | METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004037789-A2 | METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | RAF1 2/4885RIPK2 928/4885MAPK13 134/4885 |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | UROD, UTS2R, SLC14A1 | RAF1 2980/4885RIPK2 4070/4885MAPK13 593/4885 |
| US-20060199844-A1 | Methylene urea derivatives | BRAF, RAF1, CMPK1 | RAF1 2/4885RIPK2 928/4885MAPK13 134/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | RAF1 2/4885RIPK2 928/4885MAPK13 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.